Antiandrogen News and Research

RSS

Clinical trial of ENZAMET shows promising results for men with advanced prostate cancer

A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.

28 Mar 2023

Potential effects of nonoral versus oral gender-affirming estrogen therapy

A comprehensive review of research into the delivery method of estrogen treatment (e.g., oral, intramuscular injection, transdermal patch, etc.) and cardiovascular risk in transgender women and gender-diverse people found that treatment route may affect heart health, but there is not enough available data for metanalysis. The study is published ahead of print in the American Journal of Physiology-Heart and Circulatory Physiology. It was chosen as an APSselect article for November.

17 Nov 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022

Anti-androgen therapy for patients with advanced prostate cancer may fuel bone metastasis

Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

7 Jul 2021

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Researchers have described the potential of the drug spironolactone, a potassium-sparing diuretic, and anti-androgen, in preventing or alleviating the severity of COVID-19 pneumonia, and in preventing pulmonary fibrosis.

27 Jan 2021

Metastasis-free survival is strongly linked to overall survival of men treated for prostate cancer

An analysis of the phase III NRG Oncology clinical trial RTOG 9601 on men receiving salvage radiotherapy (SRT) following prostatectomy for recurrent prostate cancer indicated that, while biochemical failure (BF) was not a strong surrogate endpoint to determine overall survival (OS), metastasis-free survival (MFS) was in this patient population.

27 Oct 2020

Spironolactone may be safe to treat female pattern hair loss in breast cancer survivors

Spironolactone is not associated with increased risk of female breast cancer recurrence, according to research from the George Washington University Department of Dermatology.

9 Sep 2020

Clinical trial shows anti-tumor responses in metastatic castration-resistant prostate cancer patients

The preliminary results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy.

29 May 2020

Researchers find how GREB1 gene promotes resistance to prostate cancer treatments

Researchers have discovered how a gene involved in regulating hormone receptors may contribute to drug resistance in some prostate cancer patients.

16 Jan 2019

Traditional and new imaging methods used for prostate cancer diagnosis

Prostate cancer is the second prevent type of cancer that exists. Prostate cancer is usually a slowly progressing disease but it can sometimes manifest as an aggressive cancer. Prostate imaging is the primary way to diagnose the disease and this necessity drives its demand in the clinic.

24 Dec 2018

Research team identifies new therapeutic target for castration-resistant prostate cancer

A collaborative research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen receptor expression in prostate cancer cells, identifying a new therapeutic target for one of the deadliest forms of cancer among men.

7 Sep 2018

Combination of hormone therapy and radiotherapy halves risk of death from prostate cancer

A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.

10 May 2016

Designing AR Inhibitors Team wins AACR Team Science Award for developing prostate cancer treatment

The American Association for Cancer Research will award the ninth annual AACR Team Science Award to the Designing Androgen Receptor (AR) Inhibitors Team from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

21 Apr 2015

Androgen receptor in prostate cancer cells can activate different gene set when bound to antiandrogens

The androgen receptor in prostate cancer cells can activate different sets of genes depending on whether it binds with an androgen hormone or an antiandrogen drug, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

28 Jan 2015

Mayo Clinic researchers shed light on new mechanism by which prostate cancer develops in men

Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor - the cellular component that binds to male hormones.

11 Feb 2014

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

Radiation induces testicular cancer in male fetuses

Male fetuses of mothers that are exposed to radiation during early pregnancy may have an increased chance of developing testicular cancer, according to a study in mice at The University of Texas MD Anderson Cancer Center.

14 Feb 2012

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Targeted therapy MDV3100 is effective for patients with CRPC: Study

An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. A new multicenter study has concluded that the targeted therapy MDV3100 is safe and effective for patients with castration-resistant prostate cancer, known for its poor prognosis and limited treatment options.

15 Apr 2010

Clinical trials for two compounds show promise in advanced prostate cancer

In a paper published online this week in Science Express (the online version of Science magazine), researchers report that early clinical trials for two compounds, MDV3100 and RD162, show initial promise for patients suffering from an advanced metastatic form of the disease known as castration-resistant prostate cancer.

9 Apr 2009